ReviewFrontiers in microbiology2026
Phage endolysins as alternative antimicrobials: mechanisms, clinical progress, and emerging resistance frameworks.
Review in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Endolysin LysSte134_1 Reduces Staphylococcus Bacterial Load in Infected Wounds In Vivo.International journal of molecular sciences · 2026Article
- Construction and Characterization of the Novel Engineered Endolysin ALC005: A New Alternative Antimicrobial AgainstMicroorganisms · 2026Article
- Phage-Derived Endolysins TargetingAntibiotics (Basel, Switzerland) · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phage endolysins are increasingly recognized as alternatives to antibiotics for mitigating the growing threat of antimicrobial resistance. Since their initial identification in the 1950s, phage endolysins have been extensively demonstrated to effectively combat bacterial infections in animal models and human patients. Although phage endolysins have completed Phase II and III clinical trials, potential obstacles and challenges associated with their large-scale use remain largely undefined. This review examines the potential of phage endolysins and the challenges they face in addressing infections caused by antibiotic-resistant bacteria in the future. We conducted a comprehensive overview of the historical development, bactericidal mechanisms, clinical progress, and resistance of phage endolysins. The information presented herein may facilitate the design of novel, potent endolysins and provide strategic insights for addressing phage endolysin resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.